Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Operating Expenses (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Operating Expenses for 4 consecutive years, with $24.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Operating Expenses rose 42.96% year-over-year to $24.1 million, compared with a TTM value of $78.4 million through Dec 2023, up 26.39%, and an annual FY2023 reading of $102.6 million, up 65.34% over the prior year.
  • Operating Expenses was $24.1 million for Q4 2023 at Terns Pharmaceuticals, down from $33.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $33.2 million in Q3 2023 and bottomed at $8.7 million in Q3 2020.
  • Average Operating Expenses over 4 years is $15.2 million, with a median of $13.8 million recorded in 2022.
  • The sharpest move saw Operating Expenses grew 3.98% in 2022, then surged 91.9% in 2023.
  • Year by year, Operating Expenses stood at $8.8 million in 2020, then skyrocketed by 69.69% to $14.9 million in 2021, then rose by 13.11% to $16.8 million in 2022, then soared by 42.96% to $24.1 million in 2023.
  • Business Quant data shows Operating Expenses for TERN at $24.1 million in Q4 2023, $33.2 million in Q3 2023, and $21.2 million in Q2 2023.